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Abstract
Background: Mild parkinsonian signs (MPS) are common in older people and are associated with an increased risk
of different neurodegenerative diseases. This study prospectively evaluates the longitudinal course of cognitive
performance in older individuals with MPS.
Methods: From the TREND study, 480 individuals neurologically healthy at baseline, aged between 50 and 80 years,
with complete follow-up data for three assessments within a mean of 43.8 months, were included in this analysis.
Participants underwent a detailed cognitive test battery, evaluation of prodromal markers for neurodegenerative
diseases and history of vascular diseases at each study visit. In addition, plasma levels of amyloid-beta (Aβ)1–40 and
Aβ1–42 were evaluated longitudinally.
Results: In 52 (11 %) of the 480 participants, MPS could be detected at baseline. These individuals had cognitive
deficits significantly more often compared with controls at each time point and their cognitive performance
showed a steeper decline during follow-up. In addition, their levels of plasma Aβ1–42 were significantly lower than
those of controls, and declined more rapidly over time.
Conclusions: This longitudinal study shows that MPS are associated with cognitive decline and decrease in plasma
Aβ1–42, possibly indicating an ongoing neurodegenerative process.
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Background
Symptoms of bradykinesia, rigidity and tremor occurring in
isolation as well as in combination are common in older
people who do not meet the criteria for Parkinson’s disease
(PD) or other neurodegenerative diseases [1, 2]. These are
referred to as mild parkinsonian signs (MPS). Obviously
these symptoms can be caused by a variety of non-
neurological conditions as well as by neurological disorders.
MPS have been shown to be associated with several differ-
ent diseases and adverse health outcomes, such as PD,
dementia, functional disability and mortality [2–5]. Three
prospective studies have so far demonstrated an association
between the presence of MPS in non-demented older
adults and the development of incident dementia (including
Alzheimer’s disease (AD)) during follow-up. Wilson et al.
[6] showed already that a slight progression of MPS doubles
the risk for developing AD. Further, Louis et al. [4] showed
in a study with 1028 individuals that those with MPS at
baseline had an increased risk of 56 % for developing inci-
dent dementia after a mean follow up of 5.6 years. In a large
prospective study including 1851 individuals, the same
group found dementia in 16 % of the MPS participants after
a mean follow up of 3.7 years, with AD being the most
common type (86 %) [7]. Further, there are several cross-
sectional analyses showing an association between MPS
and mild cognitive impairment in the “prodromal phase” of
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AD [8–10]. Taken together, there is evidence that MPS
might be a “prodromal marker” for future incident demen-
tia. The “prodromal phase” of a neurodegenerative disease
is defined as the phase in which neurodegeneration is on-
going but a clinical diagnosis cannot be made. Symptoms
of the prodromal phase comprise motor and non-motor
markers (“marker” here refers to any disease indicator,
whether a symptom, sign or biomarker).
An opportunity to better estimate the possible role of
MPS as a prodromal stage of AD is the longitudinal
evaluation of clinical and biofluid markers in individuals
at risk for this form of dementia.
To the best of our knowledge, no study has yet evaluated
individuals with MPS with regard to cognitive symptoms
and biological/biochemical markers longitudinally with
biennial evaluations. To address this issue we investigated a
large cohort of healthy older individuals with and without
MPS, longitudinally over a study period of 3.5 years, using
a cognitive test battery, self-administered questionnaires for
prodromal AD markers and co-morbidities and ultrasound
for the measurement of the intima-media thickness (IMT)
of the carotids. Moreover we analysed biomaterial of the




The TREND study is a prospective follow-up study initiated
in 2009, which included individuals aged ≥50 years at base-
line and provides biennial assessments until death/autopsy.
For a detailed outline of the TREND study, as well as inclu-
sion and exclusion criteria, see Gaenslen et al. [11]. A large
assessment battery with mainly quantitative, unobtrusive
measurements designed to be repeated easily and object-
ively is being applied. To make sure that there is no bias in
data acquisition, all investigators are blinded to the results
of all other examinations. The TREND study initially com-
prised 715 participants of whom 593 individuals had three
evaluations, the prerequisite for being eligible for analyses
in this study. Of these 593 individuals, those with complete
datasets of neurological examination, a cognitive test bat-
tery and plasma levels of Aβ1–40 and Aβ1–42 were included
in this analysis. In total, 480 individuals (52 with persistent
MPS and 428 without) were analysed.
Neurological examination
Each participant underwent a standardized neurological
examination and the motor part of the revised Unified Par-
kinson’s Disease Rating Scale (MDS-UPDRS) applied by an
experienced movement disorder specialist [12]. In accord-
ance with other large-scale studies [13, 14], MPS were de-
fined as present when any of the following conditions was
met: at least two MDS-UPDRS III items ≥1; or at least one
MDS-UPDRS III item ≥2; iii) at least one MDS-UPDRS rest
tremor item ≥1. Only individuals in whom MPS were
present at all three time points were defined as individuals
with persistent MPS. Individuals in whom the results of the
neurological examination revealed PD according to the UK
Brain Bank Criteria were excluded from this analysis [15].
Assessment of demographics and medical history
Each participant underwent a structured medical interview
including demographics, medical history and medication. A
family history questionnaire was used to obtain information
on all first-degree and second-degree relatives of the partic-
ipants. Vascular risk factors were assessed with a self-
assembled medical questionnaire which includes questions
about history of ischaemic stroke or transient ischaemic at-
tack, heart attack, arrhythmia, angina pectoris, occlusive
disease of the peripheral arteries, congestive heart failure,
hypertension, hypercholesterolaemia and diabetes mellitus.
This questionnaire allows one to rate the existence or ab-
sence of the afore-mentioned disturbances (“yes/no”). In
addition, the intake of medication was recorded and used
to verify the answers.
Assessment of prodromal markers
Impaired olfaction
Olfaction was tested using the 16 Sniffin’ sticks battery
(Burghart Medizintechnik, Germany) as described by Hum-
mel et al. [16]. According to the suggestion of Hummel and
colleagues, individuals identifying less than 75 % of odours
correctly were classified as having hyposmia. Some of the
480 participants had co-morbidities prohibiting the correct
determination of olfaction (report of allergic rhinitis/cold or
nose surgery). At baseline, olfaction could not be tested in
24 participants (21 healthy controls and three individuals
with persistent MPS).
Rapid eye movement sleep behaviour disorder
Presence of rapid eye movement sleep behaviour disorder
(RBD) was determined by a self-administered RBD screen-
ing questionnaire (RBDSQ). The RBDSQ is a recently
developed questionnaire, comprising 10 items to describe
the most prominent clinical features of RBD [17]. Pres-
ence of RBD was accepted in participants with ≥5 points
in the questionnaire (sensitivity 96 % and specificity 92 %).
Depression
Depressive symptoms were assessed with the Beck
Depression Inventory I (BDI-I). The BDI-I is a 21-item
self-report questionnaire, ranging from 0 to 63 (no de-
pression, 0–10; mild to moderate depression, 11–17;
severe depression, 18–63) [18].
Intima-media thickness
Measurement of the right common carotid artery (CCA)
was performed in the first follow-up using a 5–10 MHz
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linear array transducer (VF10-5; Siemens, Erlangen,
Germany). Participants were examined in a supine position
with their head tilted backwards. The CCA was differenti-
ated from the internal jugular vein in a transverse plane,
displayed in a longitudinal scan while the course of the
CCA was followed up to the carotid bulb. IMT was mea-
sured 1 cm proximal of the carotid bulb using a fourfold
magnification of the ultrasound image [19]. The IMT of
the CCA was defined as the distance between the intima
line and the media–adventitia border at the far wall of the
CCA [20]. Measurements were documented and images
were stored. IMT was defined as pathologic if the measure-
ment was >1.0 mm [21, 22].
Cognition
Cognition was tested using an established and standardized
cognitive test battery. We used the German version of the
extended Consortium to Establish a Registry for Alzhei-
mer’s Disease neuropsychological battery (CERAD-Plus)
[23]. The battery contains the following subtests: verbal flu-
ency, Boston Naming Test, Mini Mental State Examination,
word list memory, word list recall, word list recognition,
constructional praxis, recall of constructional praxis, phon-
ematic fluency and the Trail-Making Test Parts A and B
(TMT-A and TMT-B). The TMT consists of two parts and
evaluates executive function, cognitive flexibility and work-
ing memory [24, 25]. In TMT-A, subjects have to connect
randomly spread numbers from 1 to 25 in ascending order.
In TMT-B, participants are asked to connect randomly
spread numbers (1–13) and letters (A–L) in alternating nu-
meric and alphabetical order (1–A–2–B–3–C–…–13–L).
In the case of an error, the examiner draws the attention of
the participant to the error, to allow completion of the task
without errors at the expense of additional time. The max-
imum time allowed is 180 s for TMT-A and 300 s for
TMT-B. After this time the investigator discontinues the
experiment [26]. TMT performance was calculated taking
the time needed to perform TMT-B minus the time needed
for TMT-A. This ΔTMT value prevents possible bias due
to differences in upper extremity motor speed, simple se-
quencing, visual scanning and psychomotor functioning
[24, 25]. The subtests of the CERAD-Plus battery were
grouped into four domains: executive, memory, language
and visuospatial. For the analysis of these domains, demo-
graphically adjusted z scores were used. The total score of
the CERAD battery, ranging from 0 to 100, has been shown
to provide an effective global measure of cognitive func-
tioning [27].
Biomaterial and analyses of biomarkers in plasma
Standard operating procedures were defined for the col-
lection, preparation, storage and analysis of biomaterial
obtained from the study participants.
Plasma Aβ1–38, Aβ1−40 and Aβ1–42 levels
EDTA plasma was centrifuged at 2000 × g, 4 °C for 10 min
and stored at −80 °C within 60 min after collection. Plasma
levels of Aβ1–42 and Aβ1–40 were quantified by EUROIM-
MUN Beta-Amyloid 1–42 Plasma ELISA and EUROIM-
MUN Beta-Amyloid 1–40 Plasma ELISA, respectively.
Instead of a manual procedure, the automated workup on
the ANALYZER-I (EUROIMMUN) was applied. Test spec-
ifications and characteristics for the methodology are
shown in Additional file 1. For quality control (QC) pur-
poses, QC samples were produced by pooling of EDTA
plasma samples. Some samples were used native and others
were spiked to higher concentrations with calibrator mater-
ial. After aliquoting, samples were freeze dried for long-
term stability. The samples were coded R2, R3, R6 and R8
and used over the three plasma amyloid assays. For test run
monitoring, three QC samples were included (single test-
ing) in each test run in parallel with the test samples. Only
runs with available data points for the three samples were
considered. The coloured blocks show the 95 % confidence
interval (±2 SD). For details, see Additional file 2.







Male gender (N (%)) 182 (43) 34 (65) 0.002
Age (years) 62 (50–80) 67 (51–77) <0.001
(62 ± 7) (67 ± 6)
Education (years) 14 (9–21) 13 (9–21) 0.030
(15 ± 3) (14 ± 3)
Family history PD (%) 63 (15) 8 (15) 0.838
Family history dementia (%) 167 (39) 12 (23) 0.033
MMSE (0–30) 29 (25–30) 29 (25–30) 0.173
(29 ± 1) (28 ± 1)
MDS-UPDRS-III (0–132) 0 (0–10) 4 (2–17) <0.001
(1 ± 2) (5 ± 3)
Lifetime depression (%) 155 (36) 20 (39) 0.762
Hyposmia (%) 95 (22) 15 (29) 0.216
RBD (%) 81 (19) 18 (35) 0.011
BDI-I (0–63) 6 (0–38) 6 (0–38) 0.121
(7 ± 6) (9 ± 7)
Hyperechogenic substantia
nigra (%)
106 (25) 19 (37) 0.075
ApoE4 positive (%) 94 (22) 12 (23) 0.931
Data are presented as median (range) (mean ± standard deviation) or number
(percentage of total)
ApoE4 apolipoprotein 4, BDI-I Beck Depression Inventory I, MMSE Mini Mental
State Examination, MPS mild parkinsonian signs, PD Parkinson’s disease, RBD
rapid eye movement sleep behaviour disorder, MDS-UPDRS-III Unified
Parkinson’s Disease Rating Scale part 3
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ApoE genotypes
Genomic DNA was extracted from EDTA blood using
standardized protocols. ApoE genotypes were analysed by a
multiplex SNaPshot assay (Applied Biosystems Life Tech-
nologies GmbH, Darmstadt, Germany) (PMID:15505371).
All SNPs investigated were in Hardy–Weinberg equilib-
rium (data not shown).
Statistical analysis
Statistical analysis was performed using SPSS 22.0 soft-
ware for Windows (SPSS Inc., Chicago, IL, USA). Be-
cause of the asymmetric distribution between the two
groups, differences of non-categorical data were evalu-
ated with the Wilcoxon rank-sum test. The Fisher’s exact
test was used for categorical data. Descriptive statistics
are given either as median (range) and mean ± standard
deviation for non-categorical data or as percentages of
total for categorical data. CERAD total score, TMT and
plasma levels of Aβ1–40 and Aβ1–42 have been evaluated
for each time point adjusting for age, gender and educa-
tional levels (only cognition). For the CERAD subdo-
mains, demographically adjusted z scores were used.
Differences were considered significant at p < 0.05.
Results
The 480 TREND participants had a mean duration of
total follow-up of 43.8 ± 4.2 months (baseline (BL) to
first follow-up (1FU) 19.8 ± 3.4 months; 1FU to second
follow-up (2FU) 23.6 ± 2.0 months). Persistent MPS was
present in 52 participants (11 %). The remaining individ-
uals were defined as controls.
At baseline, individuals with persistent MPS compared
with the control cohort were more often male (65 % vs.
43 %; p < 0.01), older (67 years vs. 62 years; p < 0.01),
more often had RBD (35 % vs 19 %; p = 0.01), had fewer
years of education (13 years vs. 14 years; p = 0.03) and
less often reported a positive family history for dementia
(23 % vs. 39 %; p = 0.03; see Table 1). Participants with
persistent MPS did not significantly differ from controls
in terms of prevalence of hyposmia, occurrence of life-
time depression, severity of depressive symptoms, ApoE4
status and frequency of vascular co-morbidities. Table 1
and Additional file 3 present a complete overview of all
parameters. According to the grouping criteria, MDS-
UPDRS III was significantly higher in individuals with
MPS (4 points vs. 0 points; p < 0.001).
Individuals with persistent MPS showed worse cognitive
performance compared with controls in the CERAD total
score, TMT-A and TMT-B at all three time points. Further,
they showed a non-significant trend to be worse in ΔTMT-
B – TMT-A at baseline. This difference became significant
within the follow-up evaluations (Table 2). During the
follow-up period (BL to 2FU), controls had stable results in
the longitudinally assessed CERAD total scores (p = 0.210)







BL 87 (64–100) 84 (60–96) 0.002a
(87 ± 7) (83 ± 8)
1FU 86 (56–100) 82 (44–97) 0.002a
(85 ± 8) (80 ± 8)
2FU 88 (57–100) 83 (50–98) <0.001a
(87 ± 8) (82 ± 9)
TMT-A (s) BL 34 (15–100) 39 (24–81) 0.005a
(36 ± 12) (41 ± 12)
1FU 34 (17–103) 41 (21–71) 0.016a
(36 ± 14) (43 ± 12)
2FU 33 (15–90) 40 (24–110) 0.014a
(36 ± 11) (43 ± 14)
TMT-B (s) BL 80 (34–300) 96 (47–300) 0.050a
(88 ± 33) (105 ± 40)
1FU 76 (26–300) 93 (55–300) <0.001a
(82 ± 34) (107 ± 49)
2FU 73 (25–300) 97 (47–300) 0.001a
(81 ± 37) (112 ± 61)
TMT-B – TMT-A (s) BL 46 (11–185) 54 (8–206) 0.083a
(52 ± 30) (64 ± 40)
1FU 40 (5–243) 51 (13–229) 0.001a
(46 ± 29) (64 ± 43)
2FU 39 (0–230) 52 (19–265) 0.004a
(46 ± 33) (70 ± 54)
Executive domain BL 0.406 ± 1.0 0.136 ± 1.0 0.288
1FU 0.690 ± 1.2 0.215 ± 1.1 0.010
2FU 0.887 ± 1.3 0.368 ± 1.1 0.014
Memory domain BL 0.002 ± 0.8 0.028 ± 0.8 0.862
1FU 0.177 ± 0.8 0.002 ± 0.8 0.157
2FU 0.169 ± 0.9 0.124 ± 0.8 0.463
Language domain BL 0.416 ± 0.7 0.370 ± 0.7 0.956
1FU 0.004 ± 0.7 −0.042 ± 0.7 0.575
2FU 0.343 ± 0.7 0.121 ± 0.7 0.124
Visuospatial
domain
BL 0.284 ± 0.9 0.221 ± 1.3 0.073
1FU 0.431 ± 0.9 0.074 ± 1.3 0.697
2FU 0.041 ± 1.0 0.488 ± 1.2 0.115
Values are presented as median (range) (mean ± standard deviation) for the
CERAD total score and the TMT. For the four subdomains, values are
presented as mean ± standard deviation of demographically adjusted z scores
ap values were corrected for age, gender and years of education
BL baseline, CERAD Consortium to Establish a Registry for Alzheimer’s Disease,
1FU first follow-up, 2FU second follow-up, MPS mild parkinsonian signs, TMT
Trail Making Test
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and TMT-A (p = 0.422) but an improvement in their per-
formance in the TMT-B (p < 0.001). In contrast, individuals
with persistent MPS showed stable results only in the
TMT-A (p = 0.684) but tended (non-significant trend) to
deteriorate in the TMT-B (p = 0.078) and in the CERAD
total score (p = 0.062) during the follow-up period. The two
groups did not differ in the memory, language or visuo-
spatial domain of the CERAD-Plus battery but differed in
the executive domain, represented by the TMT.
The overall relative risk of individuals with persistent
MPS to develop cognitive impairment (defined as being
in the fourth quartile with more than >98 sec needed for
completion of TMT-B at the 2FU) was 2.06 (95 % confi-
dence interval: 1.45–2.92; p < 0.001).
After correction for age and gender, individuals with per-
sistent MPS had significantly lower Aβ1–42 values than con-
trols at all time points (BL, p = 0.007; 1FU, p = 0.022; 2FU,
p = 0.021). In addition, Aβ1–42 values of persistent MPS par-
ticipants decreased over time, whereas the control group
remained stable over the three time points (p = 0.169).
Similar results were found for the ratio Aβ1–42/Aβ1–40.
Compared with controls in individuals with persistent
MPS, the Aβ1–42/Aβ1–40 ratio tended to be lower at 1FU (p
= 0.067) and was significantly decreased at 2FU (p = 0.033).
No significant differences were found between controls and
individuals with persistent MPS for Aβ1–38 and Aβ1–40
values either cross-sectionally or longitudinally (Fig. 1).
Further, we found highly significant correlations be-
tween the “diagnosis” of MPS and plasma level of Aβ1–42,
CERAD total score and TMT (Table 3).
Discussion
The main findings of this prospective longitudinal study
are the associations of MPS with both cognitive deficits
and low plasma Aβ1–42 levels, as well as the progression
of cognitive deterioration and plasma Aβ1–42 reduction
in individuals with MPS but not in those without.
In this prospective study of neurologically healthy
older adults, the phenomenon of persistent MPS is asso-
ciated with higher age and lower education but not with
other known risk factors for dementia such as ApoE4
positive status, family history for dementia or vascular
diseases. This is in line with a large prospective study
which found no association of MPS with these risk fac-
tors but still found an increased risk for dementia in in-
dividuals with baseline MPS [4].
The cognitive profile of participants with persistent
MPS was worse than that of the control group. Individuals
with persistent MPS were significantly worse in the cogni-
tive tests at all time points investigated (except for
ΔTMT-B–TMT-A at baseline) and further showed a non-
significant trend for cognitive decrease over time. These
results suggest that individuals with persistent MPS might
be in a prodromal phase of dementia and might progress
to more severe cognitive conditions.
Aβ1–42 is probably the most studied biofluid marker for
the prediction of cognitive decline or dementia in neurode-
generative research. We found that individuals with persist-
ent MPS had reduced plasma levels of Aβ1–42 at all study
time points and that their levels decrease during the obser-
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Fig. 1 Levels of plasma Aβ1–38, Aβ1–40 and Aβ1–42 in individuals with mild parkinsonian signs (MPS) and controls. a Aβ1–38, b Aβ1–40, c Aβ1–42 and d
ratio Aβ1–42/Aβ1–40. Individuals with persistent MPS had significantly lower Aβ1–42 values than controls at all three time points. In addition, Aβ1–42
values and the ratio Aβ1–42/Aβ1–40 of persistent MPS participants decreased over time, whereas the control group remained stable. No significant
differences between controls and individuals with persistent MPS were found for Aβ1–38 and Aβ1–40 values either cross-sectionally or longitudinally. Aβ
amyloid-beta, BL baseline, 1FU first follow-up, 2FU second follow-up
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(CSF) Aβ1–42 levels are reduced to a level indicative for AD
5–10 years before the onset of dementia [28], with the first
changes estimated to occur more than two decades before
related cognitive decline [29], one could suggest that the re-
duced levels of Aβ1–42 in the plasma of individuals with
persistent MPS are somehow related to CSF changes of
Aβ1–42. Consequently, a reduction of plasma Aβ1–42 may
be related to the prodromal phase of AD. In contrast to
CSF Aβ1–42, there are only few studies on plasma Aβ1–42
with inconsistent results. In cross-sectional studies of indi-
viduals with AD and mild cognitive impairment, lower [30],
unchanged [31, 32] or higher [33] levels of Aβ1–42 have
been found. A problem of these cross-sectional studies is
the relatively low number of participants. The even fewer
longitudinal studies measured Aβ in healthy individuals
only once at baseline to evaluate the risk of AD, but they
did not evaluate the course of Aβ in the prodromal phase.
For example, Sundelof et al. found an association of re-
duced Aβ1–42 and increased risk of AD while Mayeux et al.
found an association between high levels of Aβ1–42 and in-
creased risk for AD [34, 35]. Our study is therefore the first
reporting repeated measurements of Aβ1–42.
Although plasma Aβ1–42 changes are small, the finding
may still be of relevance because probably a (small) sub-
group of individuals with persistent MPS will develop
AD. It is also possible that the reduction of Aβ1–42
plasma levels in blood occur later than in CSF. Further
follow-up of this study and other studies measuring
plasma levels of Aβ1–42 would be of great interest be-
cause collection of blood is easier, less invasive and can
be done in greater cohorts than collection of CSF.
The strength of this study is the prospective longitudinal
study design. Moreover, our MPS cohort only included in-
dividuals with persistent MPS over the whole observation
period, thereby reducing confounders such as individual
daily condition (e.g. well rested, mood or nervousness)
and inter-rater differences. Most former studies defined
their cohort based on one single evaluation but motor
signs, especially when they are less distinct, can fluctuate.
By taking only individuals with persistent MPS into ac-
count, we reduced the amount of false positives and ana-
lysed a more specific group at risk for neurodegeneration.
A limitation of this analysis is the relatively short follow-
up period of a median of 3.7 years. However, we were able
to find significant differences in cognition and Aβ1–42
levels. It is highly probable that these effects become even
stronger with a longer follow-up period. Moreover, despite
the possible influence of depression on cognitive perform-
ance, we did not exclude participants which might be clin-
ically depressed (BDI >18), because the number of those
severely depressed individuals was low and equally distrib-
uted between the two groups (MPS 9 % and HC 7 %).
Therefore, we do not think that the results will be influ-
enced substantially. Additional studies are warranted for
further validation.
Conclusion
Taken together, low cognitive performance and plasma
Aβ1–42 levels which decrease over time seem to be associ-
ated with persistent MPS. This suggests that, at least in a
statistically relevant subgroup of individuals with persistent
MPS, an underlying neurodegenerative process associated
with AD pathology may be present. The potential of the
“syndrome”MPS as a predictive marker for future neurode-
generative diseases should therefore be further explored.
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Additional file 1: is Table S1 presenting test specifications and
characteristics for the methodology. (DOCX 17 kb)
Additional file 2: is a figure showing ELISA test run monitoring. Three
QC samples were included (single testing) in parallel with the test
samples. Only runs with available data points for the three samples were
considered. The coloured blocks show the 95 % confidence interval (±2
SD). (PPTX 8306 kb)
Additional file 3: is Table S2 presenting surrogate markers of risks and co-
morbidities. Participants with persistent MPS did not significantly differ from
controls in terms of frequency of vascular co-morbidities. (DOCX 11 kb)
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CERAD total score −0.16***
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parkinsonian signs, TMT Trail Making Test
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